Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022

Rhea-AI Summary

Revolution Medicines, a clinical-stage oncology company, will announce its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call and webcast are scheduled for the same day at 4:30 p.m. Eastern Time to discuss the results and recent corporate developments. Investors can access the live webcast and archived version on the company’s website. Revolution Medicines focuses on developing novel targeted therapies for RAS-addicted cancers, including a range of RAS(ON) Inhibitors and Companion Inhibitors.

Positive

• Upcoming financial results announcement on February 28, 2022.
• Scheduled conference call and webcast to discuss corporate developments.

Negative

• None.

Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time

REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2021 on February 28, 2022, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time during which members of Revolution Medicines’ senior management team will discuss financial results for the quarter and full year, and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit the “Events & Presentations” page of Revolution Medicines’ website at: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the Company's website for at least 14 days.

To listen to the live conference call, please dial (833) 423-0425 or (918) 922-3069 and request the Revolution Medicines call (conference ID: 9672794).

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6236 (RAS^MULTI), RMC-6291(KRAS^G12C), RMC-9805 (KRAS^G12D) and RMC-8839 (KRAS^G13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

Contacts:
For Investors:
Vida Strategic Partners
Stephanie Diaz
415-675-7401

For Media:
Vida Strategic Partners
Tim Brons
415-675-7402

FAQ

When will Revolution Medicines report its financial results for 2021?

Revolution Medicines will report its financial results for the fourth quarter and full year 2021 on February 28, 2022, after market close.

What time is the Revolution Medicines conference call on February 28, 2022?

The conference call is scheduled for 4:30 p.m. Eastern Time on February 28, 2022.

How can I access the Revolution Medicines conference call webcast?

The conference call and webcast can be accessed on the 'Events & Presentations' page of Revolution Medicines' website.

What therapies is Revolution Medicines developing?

Revolution Medicines is developing targeted therapies for RAS-addicted cancers, including RAS(ON) Inhibitors and Companion Inhibitors.